Investor Presentaiton

Oncology Opdivo Opdualag TIGIT Bispecific DGK Inhibitor AR LDD Ongoing Phase 2 studies to inform Phase 3 program 1L HCC1 nivolumab + relatlimab + bevacizumab VS nivolumab + bevacizumab Opdualag 2L + HCC (Post TKI)² 1L Stage IV NSCLC³ nivolumab + relatlimab VS nivolumab nivolumab + relatlimab + chemo VS nivolumab + chemo Key takeaways from Phase 2 studies inform and potentially de-risk the Phase 3 program Ill Bristol Myers Squibb™ 1. NCT05337137; 2. NCT04567615; 3. NCT04623775 Not for Product Promotional Use 101

View entire presentation